E. Frair - Concepedia

Author

E. Frair

The Ohio State University ORCID

Also Known As

E Frair, E. Frair, Emma C. Frair, Emma Frair

Publications

315

Citations

H-Index

Concepts

All Affiliations

The Ohio State University Nationwide Children's Hospital University of Utah

About

E. Frair is an author at The Ohio State University specializing in medicine, cell biology, and glioma.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	2	2	150
2	Cell Biology	2	2	150
3	Immunology	1	1	26
4	Cell Signaling	1	1	124
5	Molecular Neuroscience	1	1	124

E. Frair

Publications

298

Citations

H-Index

Page 1

	Year	Citations
PRMT5–PTEN molecular pathway regulates senescence and self-renewal of primary glioblastoma neurosphere cells Yeshavanth Banasavadi‐Siddegowda, Luke Russell, E. Frair, Oncogene Neuro-oncologyMolecular NeurosciencePrimary GlioblastomaCell RegulationCellular Senescence	2016	124
Lack of Toxicity in Nonhuman Primates Receiving Clinically Relevant Doses of an AAV9.U7snRNA Vector Designed to Induce <i>DMD</i> Exon 2 Skipping Liubov V. Gushchina, E. Frair, N. Rohan, Human Gene Therapy	2021	39
A first-in-human phase I/IIa gene transfer clinical trial for Duchenne muscular dystrophy using rAAVrh74.MCK.GALGT2 Kevin M. Flanigan, Tatyana A. Vetter, Tabatha R. Simmons, Molecular Therapy — Methods & Clinical Development	2022	31
Systemic delivery of an AAV9 exon-skipping vector significantly improves or prevents features of Duchenne muscular dystrophy in the Dup2 mouse Nicolas Wein, Tatyana A. Vetter, Adeline Vulin, Molecular Therapy — Methods & Clinical Development Duchenne Muscular DystrophyImmunologyAav9 Exon-skipping VectorDegenerative DiseaseGene Vector	2022	26
Automated immunofluorescence analysis for sensitive and precise dystrophin quantification in muscle biopsies Tatyana A. Vetter, Stefan Nicolau, A. Bradley, Neuropathology and Applied Neurobiology	2021	20
CRISPR-Cas9 homology-independent targeted integration of exons 1–19 restores full-length dystrophin in mice Anthony A. Stephenson, Stefan Nicolau, Tatyana A. Vetter, Molecular Therapy — Methods & Clinical Development	2023	17
Absence of Significant Off-Target Splicing Variation with a U7snRNA Vector Targeting <i>DMD</i> Exon 2 Duplications Nicolas Wein, Diane M. Dunn, Megan A. Waldrop, Human Gene Therapy	2021	15
Persistence of exon 2 skipping and dystrophin expression at 18 months after U7snRNA-mediated therapy in the Dup2 mouse model Liubov V. Gushchina, A. Bradley, Tatyana A. Vetter, Molecular Therapy — Methods & Clinical Development	2023	14
Systemic PPMO-mediated dystrophin expression in the Dup2 mouse model of Duchenne muscular dystrophy Liubov V. Gushchina, Tatyana A. Vetter, E. Frair, Molecular Therapy — Nucleic Acids	2022	12

Page 1